HB0043 not checked
Huahai Pharmaceutical (Huaota)
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Hidradenitis Suppurativa, Acne Vulgaris
- Main trialPhase 1/2
- “The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe HS.”In the company’s words, NCT06895499 on ClinicalTrials.gov
Other drugs for Hidradenitis Suppurativa
- RuxolitinibIncyte · Novartis · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- PovorcitinibIncyte Corporation · Phase 3
- LutikizumabAbbVie · Phase 3
- RemibrutinibNovartis · Phase 3
- BFB759Bluefin Biomedicine, Inc. · Phase 2/3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 30 Jan 2026 | Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients. | |
| Phase 1/2Not yet recruiting | 27 Oct 2026 | A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris. | |
| Phase 1Completed | 12 Feb 2026 | A Study to Evaluate Single-dose of HB0043 in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026